نتایج جستجو برای: پادتن anti cd20
تعداد نتایج: 366198 فیلتر نتایج به سال:
خلاصه سابقه و هدف: واکسیناسیون هپاتیت b حداقل در 90 درصد موارد همراه با تولید آنتی بادی خوب بوده است ولی در مطالعات متعددی دیده شده که سطح این آنتی بادی به مرور زمان کاهش می یابد. از آنجا که میزان کاهش در جوامع مختلف متفاوت است، مطالعه ی حاضر به منظور تعیین سطح سرمی پادتن هپاتیت b علیه آنتی ژنs در کودکان 7 تا 9 ساله ی واکسینه شده ی روتین کشوری در شهر زنجان در سال 1382 انجام شد. مواد و روش ها: د...
Abstract Background Tumor-targeted nanoparticles hold great promise as new tools for therapy of liquid cancers. Furthermore, the therapeutic efficacy can be improved by enhancing cancer cellular internalization. Methods In this study, we developed a humanized bispecific antibody (BsAbs: CD20 Ab-mPEG scFv) which retains clinical anti-CD20 whole (Ofatumumab) and is fused with an anti-mPEG single ...
Although anti-CD20 immunotherapy effectively treats human lymphoma and autoimmune disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally unknown. To address this, anti-mouse CD20 mAbs were used in a mouse model in which the extent and kinetics of tissue B cell depletion could be assessed in vivo. CD20 mAb treatment depleted most mature B cells within 2 day...
Despite the clinical success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about its mechanism of action. Here we show that the ability of mAbs to translocate CD20 into low-density, detergent-insoluble membrane rafts appears to control how effectively they mediate complement lysis of lymphoma cells. In vitro studies using a panel of ...
Antibody-based therapies, both unconjugated antibodies and radioimmunotherapy, have had a significant impact on the treatment of non-Hodgkin lymphoma. Single-agent rituximab is an effective therapy, but it is being increasingly used with combination chemotherapy to improve the objective response and its duration. The approved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (131)I...
BACKGROUND Immunotherapy has been explored as a new therapy for B cell lymphoma, which is a non-Hodgkin's lymphoma. Because CD20 is a B lymphocyte-specific marker, anti-CD20 single chain-tagged T lymphocytes have already begun to be experimentally used in B cell lymphoma treatment, but its use is still limited because of its unspecific targeting. T cells transfected with CD28 and CD137 can sign...
ABSTRACT Introduction: Non-Hodgkin lymphoma (NHL) is a cancer that starts in lymphocytes. The main treatment for NHL is chemotherapy and radiation. Today immunotherapy is a promising therapeutic approach in the treatment of a variety cancers which is high specific unlike previous methods. Antibodies do not penetrate effectively into tumore tissues because of their large size. Whe...
Is intrathecal anti-CD20 an option to target compartmentalized CNS inflammation in progressive MS? B cells have gained enormous attention in the treatment of multiple sclerosis (MS). While our earlier pathogenic understanding of its cause primarily focused on B cell–derived plasma cells producing self-reactive antibodies, more recent findings support the theory that B cells themselves substanti...
background: targeting of cd20 antigen with monoclonal antibodies has become the mainstay in the treatment of non-hodgkin's lymphomas and immunotherapeutic depletion of malignant b cells. accessibility of antigen is one of the crucial factors in development of monoclonal antibodies against this antigen. one major problem in expression of full length cd20 is aggregation and misfolding. there...
Autoimmune hepatitis is a severe liver disease in which ~10% of patients do not respond to standard treatment. We describe a new rescue therapy using anti-CD20 monoclonal antibodies (rituximab). Complete remission was obtained and maintained by using low doses of immunosuppressive drugs with repeated anti-CD20 infusions.
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید